This grant from the Department of Defense’s Tuberous Sclerosis Complex Research Program (TSCRP) is for supporting high-impact, innovative research focused on understanding TSC pathogenesis and improving patient lives. Priority areas include genetic modifiers, preclinical models, biomarkers, adult manifestations, mTOR inhibitor effects, novel diagnostics, and mechanisms of epilepsy and neurocognitive disorders in TSC. The Idea Development Award encourages preclinical studies, but clinical trials are not permitted. Applicants must provide relevant preliminary or published data. This opportunity specifically encourages new TSC investigators, defined as those with less than $300,000 in federal TSC research funding, or established researchers transitioning into the TSC field.
Opportunity ID: 233120
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | W81XWH-13-TSCRP-IDA |
| Funding Opportunity Title: | DoD Tuberous Sclerosis Complex Idea Development Award |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement Grant |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 4 |
| Assistance Listings: | 12.420 — Military Medical Research and Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | May 03, 2013 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | Jul 11, 2013 |
| Current Closing Date for Applications: | Jul 11, 2013 |
| Archive Date: | Aug 10, 2013 |
| Estimated Total Program Funding: | $3,200,000 |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: | – |
Additional Information
| Agency Name: | Dept. of the Army — USAMRAA |
| Description: | The mission of the TSCRP is to encourage innovative research aimed at understanding the pathogenesis and manifestations of TSC to improve the lives of individuals with TSC. Within this context, the FY13 TSCRP encourages applications that address one or more of these vital program Focus Areas: Genetic, epigenetic, and non-genetic modifiers of TSC. Preclinical models and therapeutic strategies (e.g., cytotoxic agents, combination therapies). Biomarkers for early detection, prognosis, and prediction of treatment outcomes (such as serum markers, imaging, electrophysiology, prenatal testing, and pharmacogenetics). Impact of TSC manifestations in adults (e.g., care management, age-specific pathogenesis, epidemiology, renal, reproductive issues, and lymphangioleiomyomatosis [LAM]). Long-term benefits and effects of mTOR inhibitors or other agents. Novel strategies for diagnosis, treatment, and prevention of TSC manifestations including those geared toward early identification and intervention. Cellular and molecular mechanisms of TSC and LAM pathogenesis. Causes and treatment of epilepsy in TSC. Causes and treatment of TSC-associated neurocognitive disorders including cognitive impairment, and psychiatric, behavioral, and sleep disorders. The FY13 TSCRP Idea Development Award supports high-impact, innovative research that will drive the field of TSC research forward. Preclinical studies are encouraged, but clinical trials are not allowed. Applications must include preliminary or published data that is relevant to TSC and the proposed research project. The TSCRP encourages applications for the Idea Development Award from new investigators including but not limited to: New investigators in TSC who have not received more than $300,000 in total direct costs for TSC research as a Principal Investigator (PI) of one or more federally funded, non-mentored peer reviewed awards. Established independent investigators in an area other than TSC seeking to transition into a career in TSC research. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
CDMRP Help Desk
301-682-5507 help@cdmrp.org Email:help@cdmrp.org |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 233120 Full Announcement-1 -> tscrp_fy13 ida pa_gg.pdf
Packages
| Agency Contact Information: | CDMRP Help Desk 301-682-5507 help@cdmrp.org Email: help@cdmrp.org |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| 12.420 | PKG00176397 | May 03, 2013 | Jul 11, 2013 | View |
Package 1
Mandatory forms
233120 RR_SF424_1_2-1.2.pdf
233120 PerformanceSite_1_4-1.4.pdf
233120 RR_Budget-1.1.pdf
233120 RR_KeyPersonExpanded_1_2-1.2.pdf
Optional forms
233120 RR_SubawardBudget30-1.2.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
